As an early funder of Dyne Therapeutics, CureDuchenne is pleased to share that Dyne has dosed the first participant in their clinical trial in Duchenne amenable to skipping exon 51.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on SRP-5051 […]
Published program data shows Dyne’s FORCE™ platform achieves enhanced exon skipping and prolonged dystrophin restoration in Duchenne in vivo mdx mouse model CureDuchenne provided funding to Dyne Therapeutics and we […]
Accessible gaming for people with Duchenne Individuals with Duchenne are living at a time when technology is helping to make the digital world more accessible and the real world more […]
Annual Austin Event Raises Funds to Find a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (July 21, 2022) – CureDuchenne, a leading global nonprofit focused on funding and finding […]
Event Has Raised More Than $4.6 Million over the Last Decade to Find a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (July 19, 2022) – CureDuchenne, a leading global […]
Kevin Flanigan, MD is a leading expert in the development of gene therapies for Duchenne, and the director of the Center for Gene Therapy in the Abigail Wexner Research Institute […]
Sarepta Therapeutics Shares Clinical Data and Integrated Analysis.
Significant decreases in key biomarkers of muscle damage.
